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Abstract: Exemestane is an irreversible inhibitor of the aromatase enzyme, which is a key component in the production of estrogen. 
The majority of breast cancers are sensitive to the proliferative effects of estrogen. Exemestane is approved for the adjuvant treatment 
of postmenopausal women with breast cancer after 2 to 3 years of tamoxifen therapy, based on a 32% improvement in disease-free 
survival compared with 5 years of tamoxifen alone (P , 0.001). Exemestane has also shown clinical benefits as an upfront therapy. The 
safety profile of exemestane shares some side effects with tamoxifen (hot flashes and arthralgia), but is not associated with an increased 
risk of endometrial cancer or thromboembolic events. This review will discuss in detail the efficacy and safety of exemestane in early 
breast cancer.
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Introduction
The majority of breast cancers (∼61%) express the 
estrogen  receptor,1  which  typically  correlates  with 
hormone  responsiveness  for  growth  and  prolifera-
tion (Fig. 1A); therefore, treatment approaches have 
involved  inhibition  of  hormone  signaling  using 
selective estrogen receptor modulators (SERMs) or 
aromatase inhibitors (AIs).2–4 While SERMs typically 
block estrogen from binding to its receptor, tamoxifen 
can also bind the nuclear estrogen receptor and affect 
the transcription of estrogen-regulated type II genes 
(Fig.  1B).3  Aromatase  inhibitors  decrease  estrogen 
levels by affecting a key component of the produc-
tion pathway, aromatase cytochrome P450 (CYP19; 
Fig. 1C).3,5,6 The aromatase cytochrome P450 enzyme 
is  involved  in  the  conversion  of  C19  androgens 
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Figure 1. The hormone signaling pathway and its inhibition as therapy in breast cancer. A) Estrogen receptor signaling. B) Receptor signaling inhibited by 
the selective estrogen receptor modulator tamoxifen and c) by aromatase inhibition.
Abbreviations: A, androstenedione; AF, activating function; AND-5, androstenediol-5; AND-5S, androstenediol-5 sulfate; DHEA, dehydroepiandrosterone; 
DHEA-S, dehydroepiandrosterone sulfate; E, estrogen; E1, estrone; E2, estradiol; ER, estrogen receptor; ERE, estrogen response element; RNA pol ii, 
ribonucleic acid polymerase ii; T, tamoxifen. panels A and B reprinted with permission from Johnston SR 2005.3 panel C adapted with permission from 
Labrie F, Luu-The v, Lin Sx, et al. J Mol Endocrinol 25:1–16 © Society for Endocrinology (2000).6Adjuvant exemestane in breast cancer
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to  aromatic  C18  estrogens,  primarily  in  the  ovary, 
testis, and adrenal gland.5 The aromatase cytochrome 
P450 enzyme is also active in peripheral tissues (fat, 
muscle, liver, and both epithelial and stromal breast 
cells).5,7 Physiologic studies of the aromatase enzyme 
have revealed its involvement in energy balance and 
bone maintenance in addition to its sexual hormonal 
actions.5
Aromatase was recognized as a therapeutic target 
for the treatment of hormone-dependent conditions 
such as gynecomastia and breast cancer approximately 
40 years ago.5 Developed at the same time as tamox-
ifen, the first-generation AI, aminoglutethimide, was 
nonselective  (inhibiting  adrenal  steroidogenesis  as 
well as thyroid organification of iodine) and equally 
effective at reducing peripheral estrogen production 
as the standard surgical treatments for breast cancer at 
that time.5 However, aminoglutethimide did not block 
ovarian estrogen production and was not appropriate 
in premenopausal women with breast cancer, possi-
bly because of the interruption of the estradiol nega-
tive feedback and subsequent rise in luteinizing and 
follicle-stimulating hormones.5,8 Compared with the 
antiestrogen tamoxifen, aminoglutethimide had simi-
lar clinical efficacy but a higher incidence of adverse 
events  (AEs);  therefore,  tamoxifen  became  the 
standard hormonal therapy for early and metastatic 
hormone-receptor-positive breast cancers.9–12
After  aminoglutethimide,  more  selective  com-
pounds  were  developed.  These  early  selective AIs 
exhibited competitive, irreversible, and/or mechanism-
based  inhibition.13  Mechanism-based  inhibitors  are 
highly specific for the active enzyme site and were 
found  to  produce  long-lasting  inhibition,  with  less 
toxicity compared with competitive inhibitors.5,13 Fur-
ther  structure-function  studies  of  mechanism-based 
inhibitors  produced  several  generations  of  com-
pounds, resulting in the steroidal AI exemestane and 
the nonsteroidal AIs letrozole and anastrozole. Initial 
clinical studies comparing each of the AIs (anastro-
zole, exemestane, and letrozole) with the standard of 
care, tamoxifen, demonstrated the effectiveness, and 
in some endpoints, superiority, of AIs in the first-line 
treatment setting for advanced breast cancer.14–16 Addi-
tionally, exemestane demonstrated not only activity 
but also superiority to megestrol acetate (standard of 
care) in the second-line setting after progression with 
tamoxifen in patients with advanced breast cancer.17,18
Because suppression of estrogen levels has been 
associated  with  inhibition  of  the  development  of 
breast cancer in laboratory models, exemestane treat-
ment for breast cancer prevention has recently been 
investigated in the National Cancer Institute of Canada 
Clinical Trials Group (NCIC CTG) Mammary Pre-
vention.3 trial (MAP.3).19 Women (N = 4,560) with 
at least 1 of the following risk factors were random-
ized to treatment with exemestane or placebo: $60 
years of age; Gail 5-year risk score .1.66%; prior 
atypical  ductal  or  lobular  hyperplasia  or  lobular 
carcinoma in situ; or ductal carcinoma in situ with 
mastectomy. After a median follow-up of 35 months, 
there  was  a  65%  relative  risk  reduction  in  the 
annual incidence of invasive breast cancer follow-
ing treatment with exemestane (0.19% vs. 0.55%; 
hazard ratio [HR] = 0.35; 95% confidence interval: 
0.18 to 0.70; P = 0.002).19 There were no significant 
differences  between  the  exemestane  and  placebo 
groups in skeletal fractures, cardiovascular events, 
other cancers, treatment-related deaths, osteoporosis, 
or hypercholesterolemia.19
In the early breast cancer setting, large clinical tri-
als evaluating adjuvant therapy showed that any 1 of 
the 3 AIs could improve disease-free survival (DFS) 
compared  with  tamoxifen.20–27  However,  exemes-
tane trials were initially conducted in the metastatic 
breast cancer setting, and trials in the adjuvant set-
ting have been completed recently.7 In contrast, the 
anastrozole and letrozole adjuvant trials have fully 
matured.28 Therefore, physicians may be unaware of 
the utility of exemestane in the adjuvant setting. Aro-
matase inhibitors, including exemestane, have been 
evaluated as upfront monotherapy, sequential therapy 
(following  2–3  years  of  tamoxifen),  and  extended 
therapy (following 5 years of tamoxifen). This review 
focuses on exemestane and its role in the adjuvant 
treatment of early-stage breast cancer.
exemestane chemistry, 
pharmacodynamics, and 
Pharmacokinetic Profile
Exemestane  is  a  steroidal  compound  that  mimics 
the natural substrate of aromatase, androstenedione 
(Fig. 2). Exemestane is a type I inhibitor (suicide), 
forming a tight bond with aromatase at a 2.6-fold 
higher affinity than androstenedione and permanently Kittaneh and Glück
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inactivating the enzyme.5,7,29,30 A structure-function 
study has suggested that exemestane binds as a sub-
strate in the active site pocket of aromatase and is 
converted  to  reactive  intermediates  that  bind  irre-
versibly to aromatase.29 Exemestane (up to 800 mg) 
is highly specific for aromatase, and it has no detect-
able effects on the adrenal synthesis of cortisol or 
aldosterone and no apparent effects on other endo-
crine parameters.30
In 2 small, phase I studies involving postmeno-
pausal women with advanced breast cancer (N = 27 
and N = 13), a 10-mg or 25-mg dose of exemestane 
maximally suppressed circulating estradiol, estrone, 
and estrone sulfate levels (85% to 95% from base-
line) over 12 to 13 weeks of treatment.31,32 A recent 
phase I study also suggested that during exemestane 
therapy, intratumoral androgen activity was increased 
in  tissue  from  patients  with  breast  cancer  (n  =  9) 
compared with patients without exemestane therapy 
(n = 7); androgen activities could include antiprolif-
eration and may be a marker for tumor response dur-
ing exemestane treatment.33
Exemestane is administered orally, and its pharma-
cokinetics have been analyzed in healthy postmenopausal 
volunteers as well as patients with advanced breast 
cancer.30,34  In  29  healthy  postmenopausal  volun-
teers, single doses from 0.5 mg to 800 mg demon-
strated  that  exemestane  is  rapidly  absorbed  (peak 
plasma concentrations at 2 hours) and metabolized 
(undetectable 24 hours after highest dose).30 Plasma 
concentrations of exemestane were not assayed in 
volunteers receiving 25 mg or less because exemes-
tane  was  undetectable  at  4  hours  following  the 
50-mg dose. The mean area under the curve values 
from 0 to 8 hours for exemestane were 566 ng/mL 
(200 mg), 907 ng/mL (400 mg), and 1,081 ng/mL 
(800 mg), suggesting a dose-related increase up to 
400 mg. Plasma levels of the primary exemestane 
metabolite,  17-hydroexemestane,  were  less  than 
one-tenth of the corresponding exemestane concen-
trations. The maximum aromatase enzyme suppres-
sion was observed 3 days after the single exemestane 
25-mg dose and persisted for up to 5 days with the 
higher doses; however, activity was detected as low 
as 5 mg, with 50% inhibition of baseline estrogen 
and  urinary  estrone  levels.  The  distribution  and 
metabolism of exemestane were investigated using 
radiolabeled drug.34 Following oral administration, 
at least 42% of radiolabeled drug was absorbed from 
the gastrointestinal tract and was extensively distrib-
uted into tissues and metabolized into a primary and 
many secondary metabolites (,10% unchanged drug 
of total dose was evident in plasma during a 1-week 
collection). The metabolites were inactive or inhib-
ited aromatase to a lesser extent than exemestane; 
however,  17-hydroexemestane  bound  the  andro-
gen receptor with a 100-fold increased affinity than 
that  of  exemestane.  Exemestane  may  be  metabo-
lized through CYP3A4, CYP4A11, or CYP1A1/2 to 
17-dihydroexemestane,34–36  and  was  equally  elimi-
nated in the urine and feces. However, a high-fat 
meal can increase exemestane absorption by approx-
imately 40%, and exposure can be increased by up 
to 3-fold in cases of hepatic or renal insufficiency.34 
In addition, dose modifications are recommended in 
patients receiving a CYP3A4 inducer.34 Compared 
with  healthy  postmenopausal  women,  postmeno-
pausal  women  with  breast  cancer  absorb  exemes-
tane more rapidly (peak, 1.2 hours vs. 2.9 hours in 
healthy women), but have a 45% lower clearance, 
which corresponds to a 2-fold higher mean exposure 
compared with healthy women.34 Figure 2. Chemical structures of (A) exemestane and (B) and rostenedione.
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In  postmenopausal  women  with  breast  cancer, 
orally administered exemestane inhibited plasma and 
urinary estrogens with a minimally effective dose of 
25 mg. Exemestane concentrations quickly rose to 
peak levels following oral administration, and metab-
olism was also rapid and extensive. In these phase I 
studies, no serious AEs were reported, warranting fur-
ther investigation of this agent.
clinical studies using exemestane 
as Adjuvant Breast cancer Therapy
In the adjuvant setting, there have been 5 large, phase 
III trials of exemestane in postmenopausal women 
with early breast cancer, and these study designs are 
presented  in  Figure  3;21,26,37–42  for  comparison,  the 
study designs of 5 large trials of either anastrozole 
or letrozole are also included. The exemestane trials 
have evaluated both efficacy and safety in various 
5-year  adjvant  regimens:  International  Exemestane 
Study  (IES)  compared  tamoxifen  with  exemestane 
following 2 to 3 years of tamoxifen;21,38,39 Tamoxifen 
Exemestane  Adjuvant  Multicenter  (TEAM)  com-
pared exemestane with a switch strategy of tamox-
ifen (2–3 years) to exemestane, as well as upfront 
exemestane with tamoxifen (2.75 years);37,41 NCIC 
CTG MA.27 compared exemestane with anastrozole 
as upfront monotherapies (initial trial had a 2 × 2 
factorial design with or without celecoxib, but this 
approach was discontinued because of cardiac safety 
concerns  with  COX2  inhibitors);40  and  2  extended 
therapy trials with exemestane following 5 to 7 years 
of tamoxifen, National Surgical Adjuvant Breast and 
Bowel Project (NSABP) B-33,26 and Adjuvant Post-
Tamoxifen  Exemestane  Versus  Nothing  Applied 
(ATENA) (Table 1).42 The efficacy of each agent will 
be presented, followed by their safety profiles.
Efficacy
iES
The  objective  of  the  large  IES  trial  was  to  evalu-
ate  the  efficacy  of  sequential  therapy  (tamoxifen 
alone  versus  tamoxifen  followed  by  exemestane), 
with  an  event-driven  primary  endpoint  (DFS) 
(Table 2).21,38,39 At 30.6 months, there were 183 first 
events in the exemestane group and 266 in the tamox-
ifen  group.39  Exemestane  improved  DFS  by  32% 
compared with tamoxifen (HR = 0.68; P , 0.001). 
In addition, exemestane improved both distant recur-
rence (HR = 0.66; P = 0.0004) and disease-specific 
survival (HR = 0.63; P , 0.001) to a similar extent. 
Overall survival at 30.6 months was similar between 
the 2 groups (HR = 0.88; P = 0.37). At 55.7 months, 
improvement in DFS in patients treated with exemes-
tane  compared  with  tamoxifen  was  maintained 
(HR = 0.76; P = 0.0001); similarly, time to distant 
recurrence (HR = 0.83; P = 0.03) and disease-specific 
survival (HR = 0.76; P = 0.0004) results were sus-
tained.21  There  was  a  nonsignificant  trend  toward 
improvement  in  overall  survival  with  exemestane 
compared  with  tamoxifen  (HR  =  0.85;  P  =  0.08). 
At 91 months, in patients with positive or unknown 
estrogen receptor status, improvements persisted in 
DFS (HR = 0.82; P = 0.0009), time to distant recur-
rence (HR = 0.83; P = 0.01), and disease-specific sur-
vival (HR = 0.81; P = 0.001) for patients treated with 
exemestane versus tamoxifen.38 Moreover, overall sur-
vival in the exemestane groups achieved a significant 
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Figure 3. Schematic of aromatase inhibitor therapy approaches: upfront, 
sequential, and extended.
Abbreviations:  TEAM,  Tamoxifen  Exemestane  Adjuvant  Multicenter; 
iES, international Exemestane Study; NSABp B-33, National Surgical 
Adjuvant Breast and Bowel project; ATENA, Adjuvant post-Tamoxifen 
Exemestane  versus  Nothing Applied;  BiG  1–98,  Breast  international 
Group; ATAC, Arimidex, Tamoxifen, Alone or in Combination; ARNO 95, 
Arimidex-Nolvadex; ABCSG-8, Austrian Breast and Colorectal Cancer 
Study Group; iTA, italian Tamoxifen Anastrozole.Kittaneh and Glück
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improvement  compared  with  the  tamoxifen  group 
(HR = 0.86; P = 0.04). The IES trial demonstrated 
that adjuvant sequential therapy with exemestane was 
superior to tamoxifen alone with regard to clinical 
benefits in postmenopausal women with early breast 
cancer, including survival at long-term follow-up.
Team
The  objective  of  the  open-label  TEAM  trial  was 
to  evaluate  5  years  of  upfront  exemestane  versus 
sequential therapy (tamoxifen followed by exemestane). 
Postmenopausal  women  with  hormone-sensitive 
early breast cancer (N = 9,779) were randomized to 
either 5 years of exemestane 25 mg/day (n = 4,904) 
or 2 to 3 years of tamoxifen 20 mg/day followed by 
exemestane  (n  =  4,875).37,41  One  of  the  coprimary 
endpoints was DFS at 2.75 years. A DFS event was 
defined as a locoregional or distant breast cancer recur-
rence,  a  second  primary  breast  cancer,  contralateral 
breast cancer, and all-cause death. The risk of a DFS 
Table 1. Exemestane clinical trials in postmenopausal women with early breast cancer.
study patients, n study design Inclusion/exclusion 
criteria
intergroup Exemestane Study 
(iES)21,38,39
4,724 (T: 2,380; T/E: 2,362) prospective, randomized,  
double-blind phase iii  
- T vs T→E (5 years)
postmenopausal women 
with early hormone-
sensitive BC
Tamoxifen Exemestane  
Adjuvant Multicenter  
(TEAM)37,41
9,779 (E: 4,875; T/E: 4,904) prospective, randomized, open-
label, multinational phase iii  
- Upfront T vs E (2.75 years)  
- Sequential T→E vs E (5 years)
postmenopausal women 
with early hormone-
sensitive BC
MA.2740 7,576 (E: 3,789; A: 3,787) prospective, randomized, double-
blind phase iii  
- Upfront A vs E (5 years)
postmenopausal women 
with early hormone-
sensitive BC
National Surgical Adjuvant  
Breast and Bowel project 
(NSABp) B-3326
1,598 (E: 799; p: 799) prospective, randomized, double-
blind  
- Extended E vs p (5 years)
postmenopausal women 
with hormone–receptor-
positive breast cancer 
who had received 4.5 
to 5.5 years of adjuvant 
tamoxifen therapy
Adjuvant post-Tamoxifen 
Exemestane versus Nothing 
Applied (ATENA)42
411 (E: 211; NT: 200) prospective, randomized, open-
label, parallel-group  
- Extended E vs NT (5 years)
postmenopausal women 
with hormone–receptor-
positive breast cancer 
who had received 5 
to 7 years of adjuvant 
tamoxifen therapy
Abbreviations: A, anastrozole; BC, breast cancer; E, exemestane; NT, no treatment; p, placebo; T, tamoxifen.
Table 2. Clinical outcomes in the ies sequential trial.
Median 
follow-up, 
months
DFs events,  
e vs T
DFs, HR  
(95% cI;  
P value)
DFS benefit,  
% (95% cI;  
P value)
Bc-free survival, 
HR (95% cI;  
P value)
Distant 
recurrence, 
HR (95% cI;  
P value)
Os (ITT), HR  
(95% cI; 
P value)
30.639 183 vs 266 0.68 (0.56–0.82; 
,0.001)
4.7 (2.6–6.8; 
,0.05)a
0.63 (0.51–0.77; 
,0.0001)
0.66 (0.52–
0.83; 0.0004)
0.88 (0.67–1.16; 
0.37)
55.721 354 vs 455 0.76 (0.66–0.88; 
0.0001)
3.4 (0.1–6.8;  
NR)b
0.76 (0.65–0.89; 
0.0004)
0.83 (0.71–
0.99; 0.03)
0.85 (0.71–1.02; 
0.08)
9138 530 vs 622c 0.82 (0.73–0.92; 
0.0009)c
4.4 (1.8–7.2; 
,0.05)c,d
0.81 (0.71–0.92; 
0.001)c
0.83 (0.72–
0.96; 0.01)
0.86 (0.75–0.99; 
0.04)c
notes: a3 years postrandomization; b5 years postrandomization; cin patients with estrogen-receptor-positive or unknown tumors; d8 years postrandomization.
Abbreviations: BC, breast cancer; CI, confidence interval; DFS, disease-free survival; E, exemestane; HR, hazard ratio; IES, Intergroup Exemestane 
Study; iTT, intent-to-treat; NR, not reported; OS, overall survival; T, tamoxifen. Adjuvant exemestane in breast cancer
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event favored exemestane but did not reach statistical 
significance  (HR  =  0.89;  P = 0.12). Upfront, initial 
monotherapy  with  exemestane  did  improve  time  to 
distant  recurrence  (HR  =  0.81;  P  ,  0.03)  and  risk 
of  relapse  (HR  =  0.85;  P = 0.05) versus tamoxifen 
at 2.75 years in the TEAM trial (Fig. 4).41 A limita-
tion of this analysis is the high proportion of patients 
who switched from tamoxifen to exemestane before   
2.75 years.
Sequential therapy with exemestane following 2 to 
3 years of tamoxifen had efficacy for DFS (HR = 0.97; 
P = 0.60), overall survival (HR = 1.00; P . 0.99), and 
time to recurrence (HR = 0.94; P = 0.29) similar to 
tamoxifen monotherapy at 5 years in the TEAM trial 
(Fig. 4).37 An exploratory analysis of the TEAM trial 
(n = 4,741) showed that body mass index (BMI) was 
not associated with the clinical outcomes at 5 years.43 
Disease relapse was 15% in all BMI groups (normal, 
overweight, and obese), and overall, the probability 
of disease-specific death and death from other causes 
was nearly equal. However, at 2.75 years there was an 
increase in DFS events among obese patients in the 
tamoxifen group compared with obese patients in the 
exemestane group (HR = 0.57; P = 0.004). Another 
TEAM  exploratory  analysis  demonstrated  that  the 
release of the IES study results did not affect discon-
tinuation rates in the sequential (tamoxifen to exemes-
tane) therapy group.44 The TEAM trial showed that 
upfront  therapy  with  exemestane  produced  similar 
clinical  benefits  to  that  of  tamoxifen  followed  by 
exemestane  in  postmenopausal  women  with  early 
breast cancer.
MA.27
The objective of the MA.27 trial was to evaluate the 
efficacy  of  upfront  exemestane  versus  anastrozole 
in postmenopausal women with early breast cancer 
(N = 7,576).40 Both exemestane 25 mg/day and anas-
trozole 1 mg/day performed equally well in all effi-
cacy endpoints at a median follow-up of 4.1 years: 
event-free survival (HR = 1.02; P = 0.85), overall 
survival (HR = 0.93; P = 0.64), distant recurrence 
(HR = 0.95; P = 0.46), and disease-specific survival 
(HR = 0.93; P = 0.62). A bone substudy in eligible 
patients with osteoporosis (n = 184) and without osteo-
porosis (n = 287) found no overall significant changes 
from  baseline  in  bone  turnover  markers.45 Among 
patients  without  osteoporosis,  there  was  less  early 
bone loss at the hip in the exemestane group com-
pared with the anastrozole group (1 year, P = 0.007); 
however,  at  2  years,  the  difference  was  no  longer 
significant (P = 0.13). Bone loss was also less at the 
lumbar spine in the exemestane group compared with 
the anastrozole group; however, the opposite trend 
was observed (1 year, P = 0.32; 2 years, P = 0.08). 
The MA.27 trial found equivalent efficacy for clini-
cal  benefits  between  upfront  adjuvant  exemestane 
and anastrozole in postmenopausal women with early 
breast cancer.
NSABp B-33 and ATENA
The objective of the NSABP B-33 and ATENA trials 
was to evaluate exemestane in the extended adjuvant 
setting,  following  5  years  of  tamoxifen.  However, 
both trials were terminated after publication of a sim-
ilarly designed trial of letrozole (NCIC CTG MA.17) 
that  reported  improvement  in  DFS  compared  with 
placebo.23,26,46,47 The NSABP B-33 trial had enrolled 
approximately 50% of the planned number of patients 
at the time of unblinding, and patient follow-up was 
continued.26 Patients in the placebo group were eli-
gible  to  receive  exemestane,  and  44%  of  patients 
in  the  placebo  group  crossed  over  to  exemestane. 
Analysis of the data by original therapy assignment 
showed a trend toward improvement in 4-year DFS 
after treatment with exemestane compared with pla-
cebo (relative risk [RR] = 0.68; P = 0.07). The time to 
2.75 years (n = 9,766)
DFS
RFS
Distant metastases
5.0 years (n = 9,766)
DFS
RFS
Distant metastases
P Value
0.12
0.05
<0.03
0.60
0.29
0.30
0.6
Favors
exemestane
Favors
tamoxifen or
tamoxifen/exemestane
0.7 0.8 0.9 1 1.1
Figure 4. Clinical outcomes of the TEAM trial at 2.75 and 5.0 years. 
Abbreviations: DFS, disease-free survival; RFS, relapse-free survival; 
TEAM, Tamoxifen Exemestane Adjuvant Multicenter. 
Data from Jones S, et al 200941 and van de velde CJ, et al 2011.37Kittaneh and Glück
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distant recurrence was not improved by exemestane 
(RR = 0.69; P = 0.13), but 4-year relapse-free survival 
was significantly longer with exemestane than with 
placebo (RR = 0.44; P = 0.004). The ATENA trial 
had enrolled almost 25% of the planned number of 
patients at the time of study discontinuation.42 Effi-
cacy results from this trial have not yet been pub-
lished. Although these 2 trials were terminated and 
extensive crossover from placebo to exemestane took 
place in the NSABP B-33 trial, a trend was observed 
for improved DFS in patients who were randomized 
to exemestane in NSABP B-33. This trend suggested 
that there might have been clinical benefit if the trial 
had been completed.
Taken together, these trials (IES, TEAM, MA.27, 
NSABP  B-33)  demonstrated  the  effectiveness  of 
exemestane in the adjuvant setting as upfront ther-
apy or following tamoxifen among postmenopausal 
women with early breast cancer. In addition to imme-
diate clinical benefits in DFS and recurrence, patients 
treated with exemestane had improved long-term sur-
vival compared with tamoxifen-treated patients.
safety and side effects
As  determined  in  these  large,  phase  III  trials,  the 
safety  profile  of  exemestane  is  similar  to  that  of 
other AIs, but somewhat different than that of tamox-
ifen (Table 3).21,37,39–41,48 Compared with tamoxifen, 
patients treated with AIs have a lower incidence of 
endometrial cancer and venous thromboembolism, a 
similar incidence of cerebrovascular events, a higher 
incidence of fractures, and a potentially higher inci-
dence  of  cardiovascular  events.49  A  recent  review 
of the effects of adjuvant endocrine therapy on car-
diovascular health in postmenopausal patients with 
breast  cancer  reported  that  there  was  no  evidence 
of increased cardiovascular risk during AI therapy 
based on comparisons with placebo, although there 
were increases in cardiovascular risk compared with 
tamoxifen.50  Because  hormonal  therapies  further 
lower  estrogen  levels  in  postmenopausal  women, 
menopause-like  effects  are  to  be  expected.  These 
effects may include hot flashes, sweating, gyneco-
logic  symptoms,  and  musculoskeletal  symptoms 
such as arthralgia and decreased bone mineral density 
(BMD).51–53 However, the type of effects from an indi-
vidual agent may relate to the specific activity of that 
agent. For example, AIs have no estrogenic activity, 
which decreases the risk for gynecologic cancers but 
increases the likelihood of losing BMD.52,54
vasomotor symptoms
The most common vasomotor symptoms associated 
with hormonal therapy are hot flashes and sweating. 
In  fact,  all  of  the  exemestane  trials  reporting AEs 
(IES, TEAM, and MA.27) listed hot flashes as 1 of the 
AEs most common to both exemestane and tamox-
ifen (Table 3).21,37,39–41,48 Sweating was also a com-
mon AE (∼18%) for both exemestane and tamoxifen 
in the IES trial.21,39 In 1 analysis, among 10 specific 
menopause symptoms explored, the mean hot flash 
score was higher at 12 months after tamoxifen than 
after exemestane (P = 0.03).48 However, the mean hot 
flash score peaked from baseline in both groups at 
3 months (33% for tamoxifen and 7% for exemes-
tane) and subsequently decreased. Certain individual 
symptoms occurred more frequently with tamoxifen 
(hot  flashes  and  vaginal  discharge)  or  exemestane 
(vaginal dryness, bone/muscle aches, and difficulty 
sleeping).
Musculoskeletal symptoms
In  the  IES  trial  at  both  30.6  and  55.7  months, 
there  was  an  increase  in  muscle  cramps/disorders 
for  tamoxifen  compared  with  exemestane.21,39  At 
30.6 months, there was also an increase in osteopo-
rosis and arthralgia for exemestane compared with 
tamoxifen.39 At 55.7 months, osteoporosis and arthri-
tis/arthralgia remained increased for exemestane, but 
there was now an increase in fractures with exemes-
tane.21 Further investigations into the fracture inci-
dence included a bone substudy, which showed that 
BMD at both the lumbar spine and hip significantly 
decreased from baseline with exemestane during ther-
apy (P , 0.0001 for both).55 Changes from baseline 
BMD were reported, similar to those in the TEAM 
substudy. By a median follow-up of 58 months, a frac-
ture had occurred in 7% of patients in the exemestane 
group and 5% of patients in the tamoxifen group; this 
translated into a 45% increased risk of fracture for the 
exemestane group (P = 0.003). However, a skeletal 
substudy that investigated BMD of patients 2 years 
after their last treatment found no difference between 
patients  treated  with  tamoxifen  or  exemestane.56 Adjuvant exemestane in breast cancer
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Table 3.   Adverse events in $10% of patients in phase iii clinical trials of exemestane.
study Adverse event exemestane 
patients, %
Tamoxifen/Anastrozolea 
patients, %
comparative   
P value
iES (N = 4,724)21,39
30.6 months Cardiovascular disease other than 
myocardial infarction 
Hot flashes 
pain or aches 
Fatigue 
insomnia 
Sweating 
Headaches 
Dizziness 
Nausea
42.6 
 
42.0 
33.2 
23.6 
19.5 
18.6 
18.6 
12.5 
10.8
39.2 
 
39.6 
29.4 
23.5 
17.4 
17.9 
16.2 
12.0 
11.1
0.016 
 
0.082 
0.001 
0.776 
0.151 
0.702 
0.035 
0.904 
0.835
55.7 months Nonischemic cardiovascular events 
Hypertension 
Arthritis 
Osteoarthritis 
Arthralgia 
Musculoskeletal pain 
Hot flashes 
Depression 
Dizziness 
Fatigue 
Headaches 
insomnia 
Nausea 
Sweating 
pain
11.3 
39.1 
17.5 
11.3 
20.8 
25.7 
42.4 
11.3 
13.9 
24.5 
19.1 
20.8 
10.9 
19.1 
13.3
11.2 
35.9 
14.6 
9.7 
15.1 
20.3 
39.9 
9.8 
13.6 
24.1 
17.2 
18.2 
11.7 
18.4 
14.3
0.96 
0.03 
0.008 
0.07 
,0.0001 
,0.0001 
0.08 
0.10 
0.82 
0.75 
0.09 
0.03 
0.41 
0.56 
0.30
TEAM (N = 9,779)37,41,48
1 year vaginal discharge 
vaginal dryness 
Bone/muscle aches 
Decreased libido 
Difficulty sleeping
12 
50 
77 
58 
60
32 
42 
70 
54 
55
,0.0001 
0.0004 
,0.0001 
0.03 
0.03
2.75 years Hot flashes/flushing 
Arthralgia
28.5 
17.9
33.3 
9.2
#0.001 
#0.001
5 years Hot flashes/sweating 
Joint disorders 
Muscle disorders 
Other MS/CT disorders 
Osteoporosis 
Nervous system disordersb 
insomnia/sleep disorders 
Metabolism/nutrition disordersc
35.0 
36.0 
11 
15 
10 
17 
13 
10
40.0 
31.0 
13 
13 
6 
14 
10 
9
,0.0001 
,0.0001 
0.0014 
0.0023 
,0.0001 
0.0004 
,0.0001 
0.051
MA.27 
(N = 7,576)40
Hot flashes 
Muscle pain 
Elevated cholesterol 
New-onset osteoporosisd 
Any clinical fracture at any time
55 
17 
15.3 
31 
10
56 
16 
17.7 
35 
9
0.24 
0.19 
0.01 
0.001 
0.91
notes: aAnastrozole was the comparator for the MA.27 trial; bExcluding dizziness, headache, nerve compression, and cerebrovascular events; cExcluding 
weight increase, abnormal liver function, and hyperlipidemia; dpatient-reported.
Abbreviations: iES, intergroup Exemestane Study; TEAM, Tamoxifen Exemestane Adjuvant Multicenter; MS, musculoskeletal; CT, connective tissue.Kittaneh and Glück
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Fracture rates were also similar after the end of  therapy. 
Therefore, ongoing assessment of BMD after exemes-
tane may not be necessary.
In the TEAM trial at 2.75 years, differences in 
the AE incidence between exemestane and tamox-
ifen included an increase in certain musculoskeletal 
events for exemestane.41 However, arthralgia was an 
AE common to both exemestane and tamoxifen.41,57 
At 5 years, muscle disorders became increased for 
tamoxifen versus exemestane, although other mus-
culoskeletal events remained increased for exemes-
tane.37 As  expected,  a  meta-analysis  of  data  from 
4  countries  participating  in  the  TEAM  trial  con-
firmed that exemestane and tamoxifen had contrast-
ing effects on bone health during therapy.58 At both 
12 and 24 months, patients treated with tamoxifen 
had increased lumbar spine BMD (1.2% and 0.2%, 
respectively), while patients treated with exemestane 
had decreased BMD (2.6% and 3.5%, respectively; 
P , 0.0001 for both time points). Similar results were 
observed for total hip BMD.
Arthralgia,  muscle  pain,  and  fractures  were 
common to both AIs in the MA.27 trial, although 
exemestane was associated with a significantly lower 
incidence of new-onset osteoporosis compared with 
anastrozole (P # 0.04 for all).40 Analysis of tissues 
from  the  MA.27  trial  indentified  polymorphisms 
in a leukemia gene (related to interleukin-17) that 
correlated  with  musculoskeletal AEs  in AI-treated 
women.59  These  preliminary  results  may  lead  to 
identification of predictive factors for musculoskel-
etal AEs during AI therapy and provide guidance for 
optimal AI therapy in individual patients. In a recent 
update of the MA.27 trial, women without osteoporo-
sis had less bone loss in the hip and lumbar spine at 
1 and 2 years during exemestane therapy compared 
with anastrozole, with a significant difference noted 
at 1 year in the hip (P = 0.007).45 Among women with 
osteoporosis, bisphosphonate therapy with calcium 
and vitamin D increased BMD during AI therapy, 
without significant differences between the 2 treat-
ment groups.
In the NSABP B-33 trial, the incidence of grade 3 
toxicities was higher with exemestane than with pla-
cebo (P = 0.03); specifically, arthralgia was more com-
mon with exemestane (1.0% vs. 0.5%, respectively).26 
The incidence of grade 4 toxicities (1% each) was 
similar in the exemestane and placebo groups. The 
incidence of fractures at 6 months after unblinding 
was  also  similar  between  groups  (28  exemestane-
treated patients and 20 placebo-treated patients).26
Gynecologic symptoms
In the IES trial at both 30.6 and 55.7 months, there 
was an increase in gynecologic symptoms in patients 
treated with tamoxifen compared with those treated 
with exemestane.21,39 Long-term endometrial effects 
were analyzed in an IES substudy.60 Abnormal endo-
metrial thickening ($5 mm) was significantly lower at 
24 months in patients treated with exemestane than 
in  patients  treated  with  tamoxifen  (36%  vs.  62%, 
respectively;  P  =  0.004). Although  this  significant 
difference  was  observed  within  6 months  of  start-
ing exemestane (P = 0.01), the incidence was simi-
lar within 12 months of therapy cessation. In another 
analysis, mean endometrial thickening at 12 months 
was 3.36 mm less in patients treated with exemestane 
than in patients treated with tamoxifen (P , 0.0006); 
17 tamoxifen-treated patients had histologically con-
firmed endometrial changes, whereas only 1 patient 
in the exemestane arm had similar changes.61 Fur-
thermore, no patients in the exemestane group had 
endometrial thickness greater than 10 mm, although 
11 patients in the tamoxifen group did (P , 0.0003). 
A long-term endometrial substudy demonstrated that 
sequential exemestane can even reverse tamoxifen-
induced endometrial effects.60
In the TEAM trial at 1 year, patients treated with 
tamoxifen had increased vaginal discharge compared 
with patients treated with exemestane. In the upfront 
exemestane arm, vaginal dryness became more com-
mon versus tamoxifen.41,48 At 5 years, vaginal dis-
charge  remained  more  common  in  patients  treated 
with tamoxifen (8% vs. 3% in the exemestane arm; 
P  ,  0.0001)  and  vaginal  dryness  remained  more 
common in patients treated with exemestane (7% vs. 
6% in the tamoxifen arm; P = 0.038).37
In  the  MA.27  trial,  anastrozole  was  associated 
with a significantly higher incidence of vaginal bleed-
ing compared with exemestane (P # 0.04).40 How-
ever, vaginal bleeding occurred in less than 2% of the 
population (n = 7,520).
Cardiovascular symptoms
In the IES trial at both 30.6 and 55.7 months, there 
was  an  increase  in  thromboembolic  disease  in  the Adjuvant exemestane in breast cancer
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tamoxifen arm compared with the exemestane arm 
(30.6 months: 1.9% vs. 1.0%, respectively; P = 0.005; 
and  55.7  months:  3.1%  vs.  1.9%,  respectively; 
P = 0.01).21,39 At 55.7 months, there was an increase in 
hypertension in the exemestane group (39.1% vs. 35.9% 
in the tamoxifen group; P = 0.03), which increased the 
incidence of overall cardiovascular events to a similar 
extent as that in the tamoxifen group.21
In  the  TEAM  trial  at  2.75  years,  there  was  an 
increase  in  thromboembolic  events  in  the  tamox-
ifen arm compared with the exemestane arm (2.3% 
vs. 0.9%, respectively; P # 0.001) and an increase 
in  hypertension  in  the  exemestane  arm  compared 
with the tamoxifen arm (3.3% vs. 2.1%, respectively; 
P # 0.001).41 At 5 years, the incidence of thromboem-
bolic events and hypertension remained increased in 
the tamoxifen and exemestane arms, respectively.37 
However, thromboembolic events occurred in 3% or 
less of the study population.
In  the  MA.27  trial,  exemestane  was  associated 
with a significantly higher incidence of atrial fibril-
lation compared with anastrozole (P # 0.02).40 How-
ever, atrial fibrillation also occurred in less than 2% 
of the population.
Lipid parameters
At 5 years in the TEAM trial, the incidence of hyper-
lipidemia  increased  in  the  exemestane  group  ver-
sus the tamoxifen group (5% vs. 3%, respectively; 
P  ,  0.0001).37  However,  in  the  Greek  substudy, 
exemestane had a neutral effect on the lipid profile 
during the first 24 months.46 Although total cholesterol 
decreased from baseline in both groups, the decrease 
only became significantly different from that in the 
tamoxifen group during months 18 to 24 (P # 0.02). 
Similar changes from baseline were observed dur-
ing months 12 to 24 in the mean low-density lipo-
protein (LDL) levels of each group (P # 0.03 in the 
tamoxifen arm). There were no significant changes 
from baseline in high-density lipoprotein (HDL) in 
either group, although the values were higher in the 
tamoxifen arm compared with the exemestane arm. 
There were no significant trends in triglyceride lev-
els in either group. In Japanese patients treated in the 
TEAM substudy, similar changes in the lipid profile 
were observed during the first year of treatment.62 In 
this Japanese substudy, anastrozole was also included 
as an adjuvant treatment. Nonetheless, there were no 
clinically meaningful changes in the lipid profile in 
either the exemestane or anastrozole group. It should 
be noted, however, that the decrease in HDL was less 
pronounced in patients treated with anastrozole com-
pared with those treated with exemestane.
In the MA.27 trial, anastrozole was associated with 
a  significantly  higher  incidence  of  hyperlipidemia 
compared with exemestane (P # 0.01).40
In the ATENA trial, only lipid parameters were 
reported.42 For the untreated and exemestane groups, 
total cholesterol and LDL levels increased from base-
line to 24 months, and triglyceride levels decreased. 
Increases  in  LDL  were  sustained  and  significant 
(P  #  0.03  for  all),  although  not  significantly  dif-
ferent between the groups (P = 0.08). Triglyceride 
level decreases were sustained and significant at all 
time points in the exemestane group (P # 0.04 for 
all) and the majority of time points in the untreated 
group, with no significant difference between groups 
(P = 0.50). Only in the untreated group was there 
a  sustained  significant  rise  in  total  cholesterol  at 
all time points (P # 0.009 for all); however, there 
was  still  no  significant  difference  between  groups   
(P = 0.68).
Cognitive function
In  an  exploratory  analysis  of  the  TEAM  trial, 
patients treated with tamoxifen processed informa-
tion more slowly than patients treated with exemes-
tane (P = 0.02). In addition, cognitive functioning in 
the areas of verbal memory and executive function 
was  lower  among  patients  treated  with  tamoxifen 
compared with healthy controls (P # 0.01 for both), 
but this was not the case among patients treated with 
exemestane.63  In  fact,  the  cognitive  functioning  of 
patients treated with exemestane was not significantly 
different from that of healthy controls.
Other adverse events
At 30.6 months in the IES trial, the other common AEs 
across the study were fatigue, insomnia, dizziness, and 
nausea.39 Patients treated with exemestane reported 
more  pains/aches,  headaches,  visual  disturbances, 
and  diarrhea  than  patients  treated  with  tamoxifen. 
At 55.7 months, fatigue and insomnia remained the 
most common other AEs for both groups, and diar-
rhea was still reported more often in the exemestane 
group.21 In addition, there was an increase in insomnia, Kittaneh and Glück
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paresthesia, and gastric ulcer in the exemestane group 
compared with the tamoxifen group.21 In the MA.27 
trial, exemestane was associated with a significantly 
higher incidence of steroid-related effects (acne, mas-
culinization, and elevated liver enzymes) compared 
with anastrozole (P # 0.04 for all).40 However, these 
events occurred in less than 2% of the population. 
In the NSABP B-33 trial, fatigue was more common 
in the exemestane group compared with the placebo 
group (0.9% vs. 0.5%, respectively).26
In general, exemestane has been well tolerated in 
clinical trials evaluating adjuvant therapy. An in-depth 
understanding of its safety profile and those of other 
AIs should guide selection of an optimal hormonal 
therapy in an individual patient, with early identifica-
tion or proactive management of AEs.
Management of adverse events
Management of AEs thought to be related to exemes-
tane  therapy  is  typically  symptomatic  in  focus. 
Algorithms exist for the management of arthralgias 
and loss of BMD.64–69 Once an arthralgia has been 
identified,  lifestyle  changes  including  exercise  and 
joint  protection  are  recommended.  Pharmacologic 
management  of  arthralgias  consists  primarily  of 
pain relief from acetaminophen, non-steroidal anti-
inflammatory drugs, and COX-2 inhibitors, increas-
ing to opioid use if necessary.64–67 For bone health, all 
women receiving an AI should also receive calcium 
and vitamin D supplementation as well as a bispho-
sphonate when indicated (T-score , –2.0, radiologic 
evidence of bone destruction, or $2 risk factors in the 
absence of  T-scores).65,68,69 In rare cases, the AI must 
be discontinued.
patient preference and Health-Related 
Quality of Life Measurements
In a quality of life (QOL) report from the IES trial, 
the  Functional  Assessment  of  Cancer  Therapy-
Breast  (FACT-B)  scores  were  generally  good  at 
baseline (before randomization), and neither tamox-
ifen  alone  nor  tamox  ifen  followed  by  exemestane 
led  patients  to  score  their  QOL  assessment  as  sig-
nificantly worse.70 An additional assessment of  the 
endocrine  subscale  revealed  that  endocrine  symp-
toms decreased from baseline during the trial period 
in  both  groups.  Among  the  individual  symptoms, 
decreases were similar between the 2 therapy groups, 
except for vaginal discharge, which was lower in the 
tamoxifen-to-exemestane group  compared  with  the 
tamoxifen monotherapy group (P , 0.001). A brief 
report  from  the  menopause-specific  QOL  substudy 
of  the  terminated  NSABP  B-33  trial  demonstrated 
no  significant  exemestane  treatment  effects  on  the 
4 domains of the QOL assessment (vasomotor, psy-
chosocial, physical, and sexual).26 However, baseline 
severity was not provided.
Other  studies  have  pointed  to  a  lack  of  strong 
patient  preference  between  other AIs.  Two  patient 
preference  trials  of  letrozole  and  anastrozole  have 
been conducted.71,72 Both trials were in the adjuvant 
setting  comparing  letrozole  with  anastrozole  in  a 
crossover design. In 1 trial (N = 72), the letrozole 
group reported fewer AEs than the anastrozole group 
reported (43% vs. 65%, respectively; P = 0.0028),72 and 
QOL was improved in the letrozole group compared 
with anastrozole (P = 0.02). There was a clear pref-
erence for letrozole over anastrozole (68% vs. 32%, 
respectively; P , 0.01). In the other trial (N = 181), 
there were no differences in the incidence of AEs, and 
no QOL differences were reported between the treat-
ment groups.71 There was also no clear patient pref-
erence for a particular AI: 31% of patients favored 
letrozole, 36% favored anastrozole, and 34% patients 
had no preference.
Patient preference may be influenced by the cost-
effectiveness of therapies. Although AI therapy has 
become a standard of care for the treatment of post-
menopausal women with early breast cancer because 
AIs significantly reduce the risk of disease recurrence 
and death, AIs do not eliminate these outcomes. Thus, 
physicians may need to evaluate the cost of long-term 
care of patients with breast cancer, including drug 
acquisition, follow-up, and AE management as well 
as QOL. Using data from the IES study, exemestane 
was shown to be more cost-effective than tamoxifen, 
producing  a  0.32  increase  in  quality-adjusted  life-
years (QALYs) and a $4,400 decrease in lifetime cost 
of cancer care.73 The data from IES were also used 
to analyze cost-effectiveness of exemestane versus 
tamoxifen based on the healthcare resources of differ-
ent countries, and exemestane was found to be cost-
effective in all instances.74–76 Exemestane increased 
QALYs by 0.12 in Canadian patients and by 0.24 in 
German  patients.74,76  In  a  comparative  analysis  of 
upfront  letrozole  and  anastrozole  and  sequenced Adjuvant exemestane in breast cancer
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exemestane, using distant disease-free year gained, 
all 3 agents were considered cost-effective compared 
with tamoxifen.77 Upfront letrozole had the largest 
gain versus tamoxifen (0.36 year). Upfront anastro-
zole had a gain of 0.26 year, and sequenced exemes-
tane had a gain of 0.16 year. However, exemestane 
was not an upfront therapy as the comparators were, 
and  the  patient  populations  were  different  in  each 
setting.
Adverse-event  management  appears  to  be  more 
costly  for  tamoxifen,  although  this  represents  the 
smallest fraction of overall cost. In the ATAC and 
BIG 1–98 studies, the yearly cost (using conversion 
factor of £1 = $1.55) of managing AEs from tamox-
ifen  ranged  from  £604  ($939)  to  £642  ($1,002), 
whereas those costs for anastrozole, letrozole, and 
exemestane were £315 ($491), £336 ($524), and £47 
($73),  respectively.78  It  should  be  noted,  however, 
that the impact for individual patients experiencing 
an AE may be much greater. For example, the cost 
(using conversion factor of £1 = $1.55) of managing 
fractures ranges from £450 ($702) for the wrist to 
£1,500 ($2,340) for the proximal humerus and £6,000 
($9,360) for the hip.78 In the 68-month analysis of the 
ATAC trial, 11% and 7.7% of patients receiving anas-
trozole  and  tamoxifen,  respectively,  experienced  a 
fracture.79 In the 25.8-month analysis of BIG 1–98, 
fractures occurred in 5.7% of letrozole-treated and 
4.0% of tamoxifen-treated patients.80
Other costs were estimated at $20,139 for the last 
3 months of terminal care in IES and $47,392 for dis-
tant disease management in BIG 1–98, and appear 
to be the greatest financial burden.81 In a retrospec-
tive analysis of patient charges in a large Midwestern 
healthcare system, it was determined that the charges 
incurred by patients with early-stage breast cancer 
were significantly lower in the 6- and 12-month peri-
ods before any recurrent event ($10,715 and $12,344, 
respectively)  compared  with  a  similar  period  after 
recurrence  ($45,855  and  $79,253;  P  ,  0.001  for 
both).82  Care  for  distant  recurrence  was  the  most 
costly, with mean charges of $57,642 and $104,502 in 
the 6- and 12-month periods, respectively, after recur-
rence.82 Similarly, using data from the Henry Ford 
Health  System,  the  mean  monthly  charges  were 
highest  for  distant  recurrence  ($37,969),  followed 
by locoregional ($10,934) and contralateral ($9,129) 
recurrence, when calculated for the year immediately 
after the recurrence.83 In the United Kingdom National 
Institute  for  Health  Research  analysis,  other  costs 
associated  with  AIs  compared  to  tamoxifen  were 
$8,032  (exemestane)  versus  $8,290,  $7,491  (anas-
trozole) versus $7,770, and $6,781 (letrozole) versus 
$7,156.81  The  percentage  increase  in  cost  is  larg-
est between letrozole and tamoxifen and is possibly 
because of a significantly reduced risk of recurrence 
at distant sites.82
Patient preference may affect long-term adherence 
to therapy, as is the case with many chronic diseases.84 
The level of compliance and adherence to therapy 
affects clinical outcomes and is the result of many 
factors.84 As expected, nonadherence is more likely if 
severe side effects are experienced.85–87 Additionally, 
nonadherence is more likely if the perceived risks 
are greater than the expected benefits.85,88 Although 
there are no adherence studies specific for exemes-
tane, 1 survey reported that 30% of patients receiv-
ing any AI (N = 622) discontinued their agent during 
the course of therapy.84,89 In addition, an examination 
of 3 healthcare databases for adherence to anastro-
zole therapy among pre- and postmenopausal women 
with early breast cancer (N = 12,391) found that non-
adherence ranged from 14% to 22% in the first year 
and 21% to 38% in the third year.90 Similarly, dur-
ing tamoxifen therapy for pre- and postmenopausal 
women in adherence trials, the proportion of patients 
adherent to therapy decreased by 13% to 22% within 
the first year and further declined 31% to 50% within 
the 5-year course of therapy.85,91,92 Therefore, if there 
is no clear evidence on which to base a medication 
choice  (such  as  among  the AIs),  allowing  patient 
preference for a medication may improve not only 
adherence but also outcomes.
Role in Disease Management
In the adjuvant setting, specific hormonal regimens 
have not been established in the treatment of post-
menopausal  women  with  hormone-sensitive  breast 
cancer.  A  recent  consensus  from  an  expert  panel 
favored an AI upfront, especially in patients with a 
high risk of relapse.93 Recurrence of breast cancer 
increases mortality, especially with distant metastases 
(eg, bone, liver, lung).94 As shown in the previously 
discussed exemestane clinical trials and in clinical tri-
als with letrozole or anastrozole,94 time to recurrence, 
risk  of  relapse,  and  time  to  distant  metastasis  are Kittaneh and Glück
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improved  with  AIs  compared  with  tamoxifen  in 
postmenopausal women with early-stage, hormone-
sensitive breast cancer. For patients with a low risk 
of relapse, the expert panel recommended use of the 
agent that would be best tolerated, in order to maxi-
mize adherence.93 In postmenopausal women, there 
may be a perception that AIs are not appropriate for 
patients with cardiovascular disease. These concerns 
may result from the meta-analysis reporting a higher 
risk of grade 3 and 4 cardiovascular AEs with AIs 
compared with tamoxifen. However, these data have 
not been substantiated in trials comparing AIs with 
placebo.50,95 Although the difference in cardiovascular 
events between AIs and tamoxifen was statistically 
significant, the absolute difference was low (would 
need to treat 160 to 180 patients to observe 1 cardio-
vascular event).95 Therefore, the perception that AIs 
increase cardiovascular risk may result more from the 
positive cardiovascular effect of tamoxifen than from 
negative effects of AIs.50
As  described,  the  expert  panel  did  not  recom-
mend a particular AI from among the approved AIs.93 
In  another  guideline,  anastrozole,  exemestane,  and 
letrozole are considered to have equal efficacy and 
may be used without preference.96 However, as noted 
in the MA.27 trial, the safety profiles of exemestane 
and anastrozole are not identical. Therefore, the 3 AIs 
may not be exactly the same, and therapy could be 
optimized for individual patients.97 Translational stud-
ies may identify prognostic markers that can improve 
the classification of individual risk for relapse and 
thereby provide guidance in selection of the optimal 
AI therapy for an individual patient.98–108 These stud-
ies may also identify predictive factors for benefit 
from each AI and possibly determine patient subsets 
that preferentially benefit from a particular AI.
Exemestane  is  approved  by  the  US  Food  and 
Drug Administration for use following 2 to 3 years 
of tamoxifen to complete 5 years of therapy in post-
menopausal  women  with  early  hormone-sensitive 
breast  cancer.34  However,  in  the  TEAM  and  BIG 
1–98  studies,  sequential  therapy  with  exemestane 
or letrozole following tamoxifen was not superior to 
upfront AI therapy.27,37 Furthermore, upfront therapy 
with anastrozole or exemestane had similar efficacy.40 
It is also feasible to switch from one AI to another if 
intolerability occurs, which may maximize the ben-
efits from AI therapy.109
Physician adherence to the recommended manage-
ment of treatment for postmenopausal women with 
early breast cancer is not optimal.110 In general, up 
to 65% of women with breast cancer do not receive 
the  recommended  treatment  regimens.110  Adju-
vant hormonal therapy is underutilized by approxi-
mately 30% of women with hormone-sensitive breast 
cancer.110 In 1study, a primary reason that patients 
did not receive recommended adjuvant therapy was 
physician perception that the risks were greater than 
the expected benefits.111 Increased physician aware-
ness  of  evidence-based  guidelines  should  improve 
management of breast cancer and clinical outcomes.
conclusions
Exemestane is indicated as an adjuvant therapy fol-
lowing  tamoxifen  in  postmenopausal  women  with 
hormone-sensitive breast cancer. However, the effi-
cacy of exemestane has been evaluated versus tamox-
ifen as an upfront monotherapy and as an extended 
therapy beyond 5 years of tamoxifen. Exemestane 
provided clinical benefits that were equal to tamox-
ifen  in  the  upfront  setting  and  trended  toward  a 
clinical benefit in the terminated, extended-therapy 
trials.
The safety profile of exemestane is well established 
and is, in general, similar to those of other AIs. The 
only  comparison  between  exemestane  and  another 
AI reported thus far has been an upfront trial with 
anastrozole showing that both AIs had equal efficacy 
and similar incidences of hot flashes and musculosk-
eletal events. The only differences were lower inci-
dences of new-onset osteoporosis and hyperlipidemia 
in patients treated with exemestane compared with 
anastrozole.
Further  direct  comparisons  of  exemestane  with 
other AIs are ongoing, and results from these trials 
may aid therapy selection.112–114 Because results are 
not expected for another 3 to 5 years, until that time, 
management decisions for adjuvant therapy in breast 
cancer must rely on evidence-based guidelines, base-
line patient characteristics, and patient preference.
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